DexCom, Inc. vs Johnson & Johnson — Stock Comparison
Q·Score Breakdown
8.8
Very Bullish
Overall
7.1
Bullish
Quality
Health
Growth
Valuation
Sentiment
DXCM
Consensus analyst target of $83.92 is 37% above current price.
JNJ
High-quality business with 26% return on equity and 22% profit margins.
⚠ earnings contracting 53% year-over-year.
Analyst Consensus
BUY
Target $83.92 (+36.8%)
24 analysts
BUY
Target $252.42 (+11.1%)
24 analysts
Fundamentals
DXCM
JNJ
26.3×
Trailing P/E
26.3×
20.1×
Forward P/E
17.9×
19.3%
Profit Margin
21.8%
61.5%
Gross Margin
68.0%
35.6%
ROE
26.4%
15.0%
Revenue Growth
9.9%
91.9%
Earnings Growth
-52.9%
—
Beta
0.33
—
Price / Book
—
$23.7B
Market Cap
$546.9B
$54 – $90
52-Week Range
$146 – $252
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →